These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15670669)

  • 21. [Alcohol-induced gastrointestinal diseases].
    Szalay F
    Orv Hetil; 2003 Aug; 144(34):1659-66. PubMed ID: 14528839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melatonin protects against alcoholic liver injury by attenuating oxidative stress, inflammatory response, and apoptosis.
    Hu S; Yin S; Jiang X; Huang D; Shen G
    Eur J Pharmacol; 2009 Aug; 616(1-3):287-92. PubMed ID: 19576882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adiponectin and alcoholic fatty liver disease.
    Rogers CQ; Ajmo JM; You M
    IUBMB Life; 2008 Dec; 60(12):790-7. PubMed ID: 18709650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-fat diet: a trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects.
    Vilar L; Oliveira CP; Faintuch J; Mello ES; Nogueira MA; Santos TE; Alves VA; Carrilho FJ
    Nutrition; 2008; 24(11-12):1097-102. PubMed ID: 18640006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High adiponectin and TNF-alpha levels in moderate drinkers suffering from liver steatosis: comparison with non drinkers suffering from similar hepatopathy.
    Stejskal D; Růzicka V; Fanfrdlová G; Kolár V; Bartek J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Jun; 149(1):93-9. PubMed ID: 16170395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
    Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocyte demand and substrate supply as factors in the susceptibility to alcoholic liver injury: pathogenesis and prevention.
    Israel Y; Orrego H
    Clin Gastroenterol; 1981 May; 10(2):355-73. PubMed ID: 7018748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.
    Radaeva S; Sun R; Jaruga B; Nguyen VT; Tian Z; Gao B
    Gastroenterology; 2006 Feb; 130(2):435-52. PubMed ID: 16472598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New concepts in the pathogenesis of alcoholic liver disease.
    Albano E
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):749-59. PubMed ID: 19090736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of alcohol in liver carcinogenesis.
    McKillop IH; Schrum LW
    Semin Liver Dis; 2009 May; 29(2):222-32. PubMed ID: 19387921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pathogenic molecular mechanisms in non-alcoholic steatohepatitis].
    Alvarez-Martínez HE; Montaño-Estrada LF; Hernández-Cruz P; Pérez-Campos E
    Rev Gastroenterol Mex; 2004; 69(3):176-83. PubMed ID: 15759791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
    Schäffler A; Schölmerich J; Büchler C
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic steatohepatitis and metabolic syndrome.
    Machado M; Cortez-Pinto H
    Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):637-42. PubMed ID: 16912563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
    Jansen PL
    Ned Tijdschr Geneeskd; 2005 Feb; 149(6):289-94. PubMed ID: 15730035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
    Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
    Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Energy balance, physical activity, and cancer risk.
    Fair AM; Montgomery K
    Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J; Choi SS; Diehl AM
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease.
    Li Z; Soloski MJ; Diehl AM
    Hepatology; 2005 Oct; 42(4):880-5. PubMed ID: 16175608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial glutathione: hepatocellular survival-death switch.
    Garcia-Ruiz C; Fernandez-Checa JC
    J Gastroenterol Hepatol; 2006 Oct; 21 Suppl 3():S3-6. PubMed ID: 16958667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study.
    Trombetta M; Spiazzi G; Zoppini G; Muggeo M
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():24-7. PubMed ID: 16225467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.